Table 13.
Effects of resveratrol formulations on cell viability (a) and ROS levels (b) in AMD patient # 11.
| (a) AMD PATIENT #11_Resveratrol Effects on Cell Viability. | |||
| Cell Viability | Percent Increase/p-Value |
Untreated
Mean ± SEM |
Resveratrol Brands
Mean ± SEM |
| AMD UN vs. AMD B1-treated | 203.4% 0.0034 |
1 ± 0.02849 | 3.034 ± 0.01950 |
| AMD UN vs. AMD B2-treated | 209% 0.0034 |
1 ± 0.02849 | 3.090 ± 0.1106 |
| AMD UN vs. AMD B3-treated | 165.9% 0.0034 |
1 ± 0.02849 | 2.659 ± 0.1311 |
| AMD UN vs. AMD B4-treated | 181.9% 0.0034 |
1 ± 0.02849 | 2.819 ± 0.01619 |
| AMD UN vs. AMD B5-treated | 61.8% 0.0034 |
1 ± 0.02849 | 1.618 ± 0.007562 |
| AMD UN vs. AMD B6-treated | 112.2% 0.0034 |
1 ± 0.02849 | 2.122 ± 0.03280 |
| (b) AMD PATIENT #11_Resveratrol Effects on ROS Levels. | |||
| Ros Levels | Percent Decrease/p-Value |
Untreated
Mean ± SEM |
Resveratrol Brands
Mean ± SEM |
| AMD UN vs. AMD B1-treated | 32.84% 0.0002 |
1 ± 0.03538 | 0.6716 ± 0.04014 |
| AMD UN vs. AMD B2-treated | 37.66% 0.0002 |
1 ± 0.03538 | 0.6234 ± 0.04212 |
| AMD UN vs. AMD B3-treated | 34.71% 0.0002 |
1 ± 0.03538 | 0.6529 ± 0.03225 |
| AMD UN vs. AMD B4-treated | 33.18% 0.0002 |
1 ± 0.03538 | 0.6682 ± 0.02027 |
| AMD UN vs. AMD B5-treated | 30.16% 0.0002 |
1 ± 0.03538 | 0.6984 ± 0.02910 |
| AMD UN vs. AMD B6-treated | 33.61% 0.0002 |
1 ± 0.03538 | 0.6639 ± 0.03013 |